| Title |
Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, December 2013
|
| DOI | 10.2147/ceor.s55779 |
| Pubmed ID | |
| Authors |
Machaon M Bonafede, Barbara H Johnson, Crystal Watson |
| Abstract |
To evaluate multiple sclerosis (MS)-related health care-resource utilization and costs prior to and after initiating natalizumab in the US. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 3 | 75% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | 9% |
| Unknown | 21 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 22% |
| Student > Bachelor | 3 | 13% |
| Researcher | 3 | 13% |
| Student > Postgraduate | 3 | 13% |
| Student > Master | 3 | 13% |
| Other | 4 | 17% |
| Unknown | 2 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 43% |
| Economics, Econometrics and Finance | 3 | 13% |
| Computer Science | 2 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Business, Management and Accounting | 1 | 4% |
| Other | 2 | 9% |
| Unknown | 4 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 January 2014.
All research outputs
#3,281,582
of 25,457,858 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#68
of 525 outputs
Outputs of similar age
#36,190
of 321,348 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#1
of 11 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 525 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,348 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.